Skip to content

Just another WordPress site

About us
What we do
Products
Careers
Contact us

Formation of Clinical Advisory Board for Lead Program R-107

Published 17 February 2023By Victoria Hayward

Categorized as Research

Post navigation

Previous post

Clinicians China licenced to HTDK Pharmaceuticals

Next post

Protecting Fiji’s Coastline

Search

Recent Posts

Douglas Pharmaceuticals named a finalist in the 2025 Manufacturer of the Year Awards
Douglas Takes Out Bronze at the 2025 Southern Cross Wayfinder Awards
Douglas continues participation in quality management program
Douglas selected for FDA’s Quality Management Maturity pilot study
R-107 Phase 2 Study Results for Treatment-Resistant Depression Accepted by Leading Scientific Journal, Nature Medicine

Recent Comments

No comments to show.

Archives

April 2025
March 2025
June 2024
May 2024
December 2023
October 2023
September 2023
August 2023
July 2023
April 2023
February 2023
October 2022
September 2022
June 2021
April 2020
November 2019
May 2019
April 2019
January 2019
December 2018
November 2018

Categories

Awards
Careers
Commercial
Corporate Responsibility
Large Dispensers
Manufacturing
Quality
Research

Douglas

Proudly powered by WordPress.